Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Infrared tech could take the pain out of IVs for lung cancer patients

NCT ID NCT07550764

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 21, 2026 · Updated 1 time

Summary

This study tests whether a special infrared light can help nurses see veins better when placing IVs in lung cancer patients receiving chemotherapy. The goal is to reduce pain, improve comfort, and strengthen trust between patients and nurses. About 160 patients will take part, with half getting the infrared-assisted IV and half getting the standard method.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

160 people

The number who actually took part.

Started

Apr 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older * Histopathologically confirmed lung cancer (small cell or non-small cell) * Receiving active systemic chemotherapy (at least one cycle completed) * Indication for a peripheral intravenous catheter for chemotherapy administration * Able to speak and understand Turkish sufficiently to communicate * Read and signed the informed consent form Exclusion Criteria: * Situations requiring emergency or life-saving catheterization * Presence of a central venous catheter (port, PICC or tunneled catheter) * Anatomical anomaly, amputation, post-mastectomy lymphedema or arteriovenous fistula in both upper extremities * Active local infection, dermatitis or impaired skin integrity at the planned catheterization site * Altered consciousness or disorientation * Mediastinal, supraclavicular or infraclavicular mass/lymphadenopathy that may affect upper extremity venous return Withdrawal Criteria: * Withdrawal of consent at any stage * Need for an off-protocol intervention (decision for central access after failure at the third attempt) * Development of an acute clinical condition preventing completion of data collection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer (diagnosis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ataturk University Research Hospital

    Erzurum, Erzurum, 25100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.